Basilea Pharmaceutica Secures $6M Non‑dilutive Grant From CARB‑X for Novel Antibiotic BAL2420
Swiss biotech Basilea Pharmaceutica announced it has received an additional US$6 million non‑dilutive grant from the non‑profit accelerator CARB‑X to fund the Phase I trial of its novel Gram‑negative antibiotic BAL2420. The funding follows six years of CARB‑X support and enables the first‑in‑human study, with the first subject dosed in March 2026.
BDC Capital Launches $110M Life Sciences Fund
Canada’s Business Development Bank of Canada (BDC) announced the launch of a new $150‑million CAD (≈$110 million USD) life sciences fund, managed by BDC Capital. The fund will target seed‑ and Series A‑stage biotech and medical‑technology companies, with initial investments of $1‑3 million...
Sidewinder Therapeutics Raises $137M in Series B Round
San Diego‑based ADC biotech Sidewinder Therapeutics announced it has closed a $137 million Series B financing to advance its bispecific antibody‑drug conjugate platform. The new capital will fund pipeline development and expand the company’s capabilities. The round was disclosed on April 8, 2026.
Life Biosciences Raises $80M to Fund Anti‑aging Gene Therapy Clinical Trial
Life Biosciences, a startup co‑founded by Harvard biologist David Sinclair, announced it has raised $80 million to support a clinical test of its anti‑aging gene therapy. The funding will be used to develop a one‑time treatment aimed at rewinding cellular aging,...
VION Biosciences Closes Acquisition of Cellular Technology Limited (CTL)
VION Biosciences announced the closing of its acquisition of Cellular Technology Limited (CTL), a provider of functional immune‑monitoring analyzers, software, consumables, and services. The deal expands VION’s capabilities in immune‑medicine, adding CTL’s ELISPOT and FluoroSpot platforms and recurring consumables, strengthening...
Gilead to Acquire Tubulis for ~$5B
Gilead has entered into a definitive agreement to acquire Tubulis, an ADC research organization, for an upfront $3.15B plus up to $1.85B in contingent milestone payments, totaling roughly $5B. The acquisition will expand Gilead’s ADC capabilities and add next‑generation assets...
Jeito Capital Closes Record $1.2B Europe-Focused Biopharma Fund
France-based Jeito Capital has closed its second fund, raising €1 billion ($1.2 billion), the largest ever for an independent European biopharma fund. The Jeito II fund will back 15‑20 clinical‑stage biopharma companies across Europe, with investment caps up to €150 million per company.
Korsana Biosciences to List on NASDAQ via Reverse Merger with Cyclerion Therapeutics
Neuroscience firm Korsana Biosciences announced a reverse‑merger with NASDAQ‑listed Cyclerion Therapeutics, creating a combined company that will trade under the ticker KRSA. The all‑stock transaction gives Korsana shareholders about 98.5% of the equity, with Cyclerion shareholders retaining 1.5%, and includes...
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9B
Neurocrine Biosciences announced a $2.9 billion cash acquisition of Soleno Therapeutics, a Bay Area biotech known for its VYKAT XR therapy for Prader‑Willi syndrome. The deal gives Neurocrine its first metabolic‑disorder therapy and aims to accelerate its obesity drug pipeline. Soleno will...
Syneron Bio Closes $150M Series B Funding Round
Syneron Bio, a biotech firm developing AI-enabled macrocyclic peptide discovery, announced the close of a $150 million Series B round. The round was led by an undisclosed international life sciences fund with co-lead investors Decheng Capital and CDH VCG, and...
Aspect Biosystems Secures $58M Canadian Government Funding for Diabetes Cell Therapy
Vancouver-based biotech startup Aspect Biosystems announced it has received $58 million in funding from the Government of Canada to advance its diabetes cell therapy platform. The grant aims to keep the breakthrough development in Canada and accelerate clinical progress, supporting...
SV Health Investors Acquires EpiVax, Expanding Healthcare Portfolio
SV Health Investors, a private healthcare investment firm, announced the acquisition of EpiVax, a bioanalytical CRO specializing in immunogenicity risk assessment for pharma and biotech companies. The deal, announced on April 2, 2026, adds a new platform investment to SVHI’s...
Beam Therapeutics Secures $500M Senior Secured Loan From Sixth Street
Beam Therapeutics announced a $500 million senior secured, long‑term non‑dilutive financing agreement with Sixth Street to support the potential commercial launch of its Risto‑Cel therapy. The deal provides a minimum $200 million drawdown and extends the company's runway through mid‑2029....
Zag Bio Raises $80M Series A to Advance Thymus‑targeted Autoimmune Therapy
Cambridge‑based biotech Zag Bio announced an $80 million Series A financing to move its bispecific antibody platform targeting central tolerance into the clinic. The funding will support development of its lead program aimed at treating autoimmune diseases by rewiring the thymus. The...
Atavistik Bio Raises $160M in Series B Funding, Including $40M Extension
Atavistik Bio announced the completion of its Series B financing, raising a total of $160 million, with $120 million closed in December 2025 and a $40 million extension in March 2026. The capital will fund the development of its allosteric...
Kailera Raises $1bn in Growth-Stage Funding Round
Kailera, a weight‑loss injectable maker, secured $1bn in a growth‑stage funding round from Atlas Venture, Bain Capital, CPP Investments, RTW Investments and Jiangsu Hengrui Pharmaceuticals. The capital will fuel its GLP‑1 product development and support an upcoming IPO in a...
Biogen to Acquire Apellis Pharmaceuticals for $5.6B
Biogen announced on March 31, 2026 that it will acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash, adding Apellis’ rare‑disease drugs Empaveli and Syfovre to its portfolio. The deal expands Biogen’s rare‑disease pipeline as its multiple‑sclerosis revenues decline.
Tempest Therapeutics Completes Acquisition of CAR‑T Assets From Factor Bioscience
Tempest Therapeutics announced the completion of its strategic acquisition of a portfolio of dual‑targeting CAR‑T assets from Factor Bioscience Inc. The all‑stock transaction adds next‑generation CAR‑T candidates, including TPST‑2003, to Tempest’s pipeline. Financial terms were not disclosed.
Kyntra Bio Completes Sale of FibroGen China to AstraZeneca
Kyntra Bio announced the completion of the sale of its FibroGen China assets to AstraZeneca, enabling full repayment of its senior secured term loan and extending its cash runway into 2028.
Kailera Therapeutics Files IPO to Fund Dual GLP-1/GIP Obesity Drug Development
Clinical-stage biotech Kailera Therapeutics filed its IPO paperwork with the SEC on March 29, 2026, seeking a Nasdaq listing under the ticker KLRA. The filing does not disclose the number of shares or proceeds, but the company plans to use...
Eli Lilly Commits $2.75B to Insilico Medicine for AI‑discovered Drug Candidates
On March 29, Eli Lilly announced a $2.75 billion corporate investment in Insilico Medicine, paying $115 million upfront and tying the remaining $2.63 billion to milestones and royalties. The deal grants Lilly global rights to develop and commercialize oral therapeutics discovered by Insilico’s AI...
Ysios Capital Launches $110M InceptionBio Fund to Build Biotech Companies
Spain’s largest life‑sciences VC, Ysios Capital, announced the launch of InceptionBio, a $110 million fund dedicated to creating biotech companies from university spin‑outs. The fund, anchored by Spain’s Centre for Technological Development and Innovation (CDTI), aims to establish at least three...
PetaSight Acquires Babbage Insight Two to Expand AI‑Led Life Sciences Research Platform
PetaSight Inc., a provider of an AI‑led operating system for life‑sciences primary market research, announced the acquisition of Babbage Insight Two Inc., a New York‑based developer of patented algorithms and data insight engines. The undisclosed deal will expand PetaSight’s platform...
VERIGRAFT Secures $10M Financing From Existing Investors to Launch Pivotal Phase II/III Trial
Swedish biotech company VERIGRAFT announced it has raised $10 million from existing investors to fund the initiation of a pivotal Phase II/III trial of its personalized tissue‑engineered vein (P‑TEV) for chronic venous insufficiency. The financing will support trial sites in...
Immutrin Secures $87M Series A to Advance ATTR‑CM Antibody Therapy
U.K.-based biotech Immutrin raised $87 million in a Series A round led by Frazier Life Sciences, with participation from Qiming Venture Partners, F‑Prime, SR One, Cambridge Enterprise Ventures and Cambridge Innovation Capital. The capital will fund the development of its lead antibody...
Cauldron Ferm Raises $13.25M in Series A2 Round Led by Main Sequence Ventures
Cauldron Ferm announced a $13.25 million Series A2 financing round led by Main Sequence Ventures, with participation from Horizons Ventures, NGS Super and SOSV. The funding will be used to scale its hyper‑fermentation technology for protein and fat production. The round...
Sanofi Invests $180M in T-Cell Engager Startup Kali
Sanofi announced a $180 million investment in California-based T-cell engager startup Kali, part of a larger deal valued at $1 billion. The funding will support Kali's development of next-generation T-cell therapies and marks Sanofi's renewed focus on the T-cell engager...
Gilead Sciences to Acquire Ouro Medicines in over $2 Billion Buyout
Gilead Sciences announced it will acquire privately held biotech Ouro Medicines for more than $2 billion, adding the experimental antibody OM336 to its immunology pipeline. The deal expands Gilead’s portfolio of autoimmune therapies as it seeks growth beyond its HIV...
Novartis to Acquire Experimental Breast Cancer Drug From Synnovation Therapeutics for $2B
Novartis announced it will acquire an experimental breast cancer drug from Delaware-based Synnovation Therapeutics in a deal valued at $2 billion upfront. The acquisition expands Novartis’s oncology pipeline and reflects its commitment to advancing cancer therapies. The transaction was reported on...
Leyden Labs Raises €50M in European Funding Round
Leyden Labs, a biotech developing an intranasal antibody spray for flu protection, announced a recent €50 million European funding boost. The round will support further development and commercialization of its mucosal protection platform. The announcement was highlighted in a podcast interview...
Earendil Labs Raises $787M in Private Funding
US-headquartered, China-rooted biotech Earendil Labs announced it has raised $787 million in private funding to expand its AI-driven drug discovery platform, which already supports a pipeline of over 40 programs. The capital will be used to accelerate development and position...
Novartis Spin‑out Atrium Therapeutics Launches with $270M Funding
Atrium Therapeutics, a spin‑out from Novartis‑owned Avidity Biosciences, has launched as an independent, publicly traded company focused on RNA therapeutics for rare genetic cardiomyopathies. The company secured $270 million in funding and entered a licensing agreement with Novartis for its RNA‑targeting...
Crossbow Therapeutics Raises $77M in Series B Funding
Crossbow Therapeutics announced a $77 million Series B financing co‑led by Taiho Ventures and Arkin BioCapital, with participation from MPM BioImpact, Pfizer Ventures, Polaris Partners and other investors. The capital will fund the development of its TCR‑mimetic antibody candidates, including lead drug...
R1 Therapeutics Raises $77.5M Series A to Advance Kidney Disease Drug
R1 Therapeutics announced an oversubscribed $77.5 million Series A round to advance its first‑in‑class hyperphosphatemia treatment for chronic kidney disease. The round was co‑led by Abingworth, F‑Prime and DaVita Venture Group. The funding will support global development, including a Phase 2b study of...
AstraZeneca Acquires FibroGen China From Kyntra Bio
Kyntra Bio completed the sale of its FibroGen China assets to AstraZeneca, enabling repayment of its senior secured term loan and extending its cash runway. The transaction was announced during Kyntra Bio's Q4 2025 earnings call on March 16, 2026.
Virdalis Raises $700K Pre‑seed Round Led by Wavemaker Impact
Singapore‑based biotech startup Virdalis closed a $700,000 pre‑seed round led by venture builder Wavemaker Impact to scale its duckweed‑derived protein for animal feed. The funding will support pilot production, talent hiring, and commercial agreements across Southeast Asia, highlighting investor interest...
MBX Biosciences Raises Additional Capital via At‑the‑market Program
MBX Biosciences, a clinical‑stage biopharmaceutical firm, reported its 2025 financial results and announced that it raised additional capital through its at‑the‑market program, boosting cash and investments to roughly $459.1 million. The funding will support its endocrine and metabolic disease pipeline through...
Deeptech Startup metaBIX Raises $1.3M in New Funding Round
Uruguayan deeptech startup metaBIX Biotech raised $1.3 million from Dalus Capital and EWA Capital, with participation from existing investors TheBoard Peru, Angel Hub, AIR Capital and Danta Fund. The capital will fund commercial expansion in Brazil and scaling of its AI‑driven...
Clene Inc Raises over $28M in Oversubscribed Registered Direct Offering
Clene Inc announced it raised more than $28 million through an oversubscribed registered direct offering, boosting its cash balance to $5.2 million as of Dec. 31, 2025 and supporting operations into 2027. The fundraising was disclosed in the company's full‑year...
Europa Biosite's Cambridge Bioscience Acquires UK Distributor Stratech Scientific
Europa Biosite announced that its UK subsidiary Cambridge Bioscience has acquired Stratech Scientific Limited, a long‑established UK life‑science distributor. The deal expands Europa Biosite’s product catalogue and strengthens its reach across UK academic and biopharma research communities. Financial terms were...
Enodia Therapeutics Acquires Kezar Life Sciences' Sec61 Assets for Up to $127M
Enodia Therapeutics announced it has acquired the Sec61‑based discovery and development assets of Kezar Life Sciences. The transaction includes an upfront payment of $1 million and potential milestone payments up to $127 million, plus royalties, bolstering Enodia’s targeted protein degradation platform and...
Mycoverse Raises €2.4M Pre‑seed Round Led by Future Food Fund and HTGF
Danish agritech startup Mycoverse announced the closing of a €2.4 million pre‑seed round to develop AI‑driven fungal biocontrol solutions for potato late blight. The round was co‑led by Future Food Fund and High‑Tech Gründerfonds, with participation from PINC, the venture arm...
BioInnovation Institute Funds 11 Life‑science Startups with €500k Convertible Loans Each
Copenhagen‑based BioInnovation Institute announced that its Venture Lab programme will support 11 early‑stage life‑science startups, each receiving a €500,000 convertible loan and access to labs, mentorship and its investor network. The 12‑month programme aims to accelerate commercialization of technologies in...
MindImmune Therapeutics Secures $5M Funding From ADDF for Alzheimer’s Immunotherapy
Cambridge‑based biotech MindImmune Therapeutics announced a $5 million investment from the Alzheimer’s Drug Discovery Foundation to advance its lead candidate MITI‑101, an antibody targeting peripheral immune pathways in Alzheimer’s disease. The funding will support IND‑enabling studies and early‑stage clinical development, building...
Cytotrait Secures £3M Seed Funding to Advance Agricultural Gene-Editing Platform
Cytotrait, a University of Manchester spinout, closed a £3 million seed round led by Northern Gritstone with participation from UK Innovation & Science Seed Fund and Northern Universities Ventures Fund. The capital will expand its MOSS platform for organelle gene editing...
SignaCor Therapeutics Raises €288k From Zinc in €1.1M Seed Round
Belfast‑based healthtech startup SignaCor Therapeutics secured a €288k investment from venture capital firm Zinc, part of a €1.1 million seed round expected to close in April. The funding will support Phase 2a trial plans and regulatory strategy for its first‑in‑class treatment for...
Prolium Bioscience Raises $50M in Series A Backed by RTW Investments
Prolium Bioscience Inc., a biotech startup developing T cell engagers, announced it has secured $50 million in a Series A round led by RTW Investments. The funding will support development of its TCE platform for multiple immunology indications.
Swiss Rockets Acquires Complete Genomics
Swiss Rockets, a Basel‑based company, announced the acquisition of Complete Genomics, taking over its CoolMPS technology and key personnel while retaining the Complete Genomics brand. The deal aims to shield the genomics business from US regulatory concerns and includes royalty...
Servier to Acquire Day One Biopharmaceuticals for $2.5B
French pharmaceutical group Servier announced a $2.5 billion all‑cash acquisition of U.S. biopharma Day One Biopharmaceuticals. The tender offer at $21.5 per share represents a 68.23% premium and is expected to close in Q2 2026.
Cognito Therapeutics Secures $105M Series C to Advance At‑Home Alzheimer’s Therapy
Cognito Therapeutics announced the closing of an oversubscribed $105 million Series C round led by Morningside Ventures, IAG Capital Partners and Starbloom Capital, with participation from Apollo Health Ventures and Benvolio Group. The funding will support a pivotal data readout, regulatory filing...
